This company has been marked as potentially delisted and may not be actively trading.

CohBar (CWBR) Competitors

CWBR vs. SBFM, FBLG, SNYR, PULM, and ALZN

Should you be buying CohBar stock or one of its competitors? The main competitors of CohBar include Sunshine Biopharma (SBFM), FibroBiologics (FBLG), Synergy CHC (SNYR), Pulmatrix (PULM), and Alzamend Neuro (ALZN). These companies are all part of the "pharmaceutical products" industry.

How does CohBar compare to Sunshine Biopharma?

CohBar (NASDAQ:CWBR) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Sunshine Biopharma has a consensus target price of $7.00, indicating a potential upside of 566.67%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Sunshine Biopharma is more favorable than CohBar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CohBar	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sunshine Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sunshine Biopharma has higher revenue and earnings than CohBar.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CohBar	N/A	N/A	-$12.18M	N/A	N/A
Sunshine Biopharma	$36.31M	0.14	-$5.97M	-$1.48	N/A

In the previous week, Sunshine Biopharma had 1 more articles in the media than CohBar. MarketBeat recorded 1 mentions for Sunshine Biopharma and 0 mentions for CohBar. CohBar's average media sentiment score of 0.00 equaled Sunshine Biopharma'saverage media sentiment score.

Company	Overall Sentiment
CohBar	Neutral
Sunshine Biopharma	Neutral

2.5% of CohBar shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 6.5% of CohBar shares are held by insiders. Comparatively, 0.0% of Sunshine Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

CohBar has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.86%. CohBar's return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CohBar	N/A	N/A	N/A
Sunshine Biopharma	-17.86%	-27.14%	-21.14%

CohBar has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500.

Summary

Sunshine Biopharma beats CohBar on 7 of the 12 factors compared between the two stocks.

How does CohBar compare to FibroBiologics?

CohBar (NASDAQ:CWBR) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

FibroBiologics has a consensus target price of $74.00, indicating a potential upside of 6,279.31%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than CohBar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CohBar	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CohBar	N/A	N/A	-$12.18M	N/A	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

In the previous week, FibroBiologics had 7 more articles in the media than CohBar. MarketBeat recorded 7 mentions for FibroBiologics and 0 mentions for CohBar. CohBar's average media sentiment score of 0.00 beat FibroBiologics' score of -0.14 indicating that CohBar is being referred to more favorably in the media.

Company	Overall Sentiment
CohBar	Neutral
FibroBiologics	Neutral

CohBar has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, FibroBiologics has a beta of 1.16, meaning that its stock price is 16% more volatile than the S&P 500.

2.5% of CohBar shares are held by institutional investors. 6.5% of CohBar shares are held by insiders. Comparatively, 13.0% of FibroBiologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CohBar's return on equity of 0.00% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CohBar	N/A	N/A	N/A
FibroBiologics	N/A	-767.07%	-195.56%

Summary

CohBar beats FibroBiologics on 6 of the 11 factors compared between the two stocks.

How does CohBar compare to Synergy CHC?

CohBar (NASDAQ:CWBR) and Synergy CHC (NASDAQ:SNYR) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

CohBar has higher earnings, but lower revenue than Synergy CHC.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CohBar	N/A	N/A	-$12.18M	N/A	N/A
Synergy CHC	$30.38M	0.19	-$12.34M	-$1.07	N/A

2.5% of CohBar shares are held by institutional investors. 6.5% of CohBar shares are held by insiders. Comparatively, 56.6% of Synergy CHC shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Synergy CHC has a consensus target price of $6.25, indicating a potential upside of 1,500.51%. Given Synergy CHC's stronger consensus rating and higher probable upside, analysts plainly believe Synergy CHC is more favorable than CohBar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CohBar	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Synergy CHC	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Synergy CHC had 1 more articles in the media than CohBar. MarketBeat recorded 1 mentions for Synergy CHC and 0 mentions for CohBar. Synergy CHC's average media sentiment score of 1.98 beat CohBar's score of 0.00 indicating that Synergy CHC is being referred to more favorably in the news media.

Company	Overall Sentiment
CohBar	Neutral
Synergy CHC	Very Positive

CohBar has a net margin of 0.00% compared to Synergy CHC's net margin of -42.59%. CohBar's return on equity of 0.00% beat Synergy CHC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CohBar	N/A	N/A	N/A
Synergy CHC	-42.59%	-19.51%	-5.29%

CohBar has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Synergy CHC has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500.

Summary

Synergy CHC beats CohBar on 7 of the 13 factors compared between the two stocks.

How does CohBar compare to Pulmatrix?

Pulmatrix (NASDAQ:PULM) and CohBar (NASDAQ:CWBR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Pulmatrix has higher revenue and earnings than CohBar.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmatrix	$7.81M	0.61	-$5.16M	-$1.41	N/A
CohBar	N/A	N/A	-$12.18M	N/A	N/A

11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 2.5% of CohBar shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by company insiders. Comparatively, 6.5% of CohBar shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmatrix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CohBar	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Pulmatrix's average media sentiment score of 0.00 equaled CohBar'saverage media sentiment score.

Company	Overall Sentiment
Pulmatrix	Neutral
CohBar	Neutral

CohBar's return on equity of 0.00% beat Pulmatrix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmatrix	N/A	-96.97%	-88.53%
CohBar	N/A	N/A	N/A

Pulmatrix has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Comparatively, CohBar has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.

Summary

Pulmatrix beats CohBar on 5 of the 8 factors compared between the two stocks.

How does CohBar compare to Alzamend Neuro?

Alzamend Neuro (NASDAQ:ALZN) and CohBar (NASDAQ:CWBR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
CohBar	N/A	N/A	-$12.18M	N/A	N/A

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 2.5% of CohBar shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by company insiders. Comparatively, 6.5% of CohBar shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Alzamend Neuro's average media sentiment score of 0.00 equaled CohBar'saverage media sentiment score.

Company	Overall Sentiment
Alzamend Neuro	Neutral
CohBar	Neutral

Alzamend Neuro currently has a consensus target price of $28.00, suggesting a potential upside of 2,516.82%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, equities research analysts plainly believe Alzamend Neuro is more favorable than CohBar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CohBar	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Alzamend Neuro has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500. Comparatively, CohBar has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

CohBar's return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
CohBar	N/A	N/A	N/A

Summary

Alzamend Neuro beats CohBar on 5 of the 9 factors compared between the two stocks.

Get CohBar News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CWBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CWBR vs. The Competition

Export

Metric	CohBar	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.19M	$904.51M	$6.25B	$12.13B
Dividend Yield	N/A	4.84%	2.78%	5.20%
P/E Ratio	N/A	1.56	20.88	25.39
Price / Sales	N/A	121.17	533.01	77.05
Price / Cash	N/A	20.07	43.29	53.47
Price / Book	0.08	7.71	9.98	6.81
Net Income	-$12.18M	-$5.06M	$3.54B	$332.87M

CohBar Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CWBR CohBar	N/A	$0.41 flat	N/A	N/A	$1.19M	N/A	N/A	10
SBFM Sunshine Biopharma	1.8938 of 5 stars	$1.06 +9.6%	$7.00 +563.5%	-14.6%	$4.72M	$36.31M	N/A	3	News Coverage Positive News High Trading Volume
FBLG FibroBiologics	3.5405 of 5 stars	$1.46 +10.6%	$74.00 +4,968.5%	-93.1%	$4.64M	N/A	N/A	10	Upcoming Earnings Gap Down
SNYR Synergy CHC	3.5252 of 5 stars	$0.32 +2.7%	$6.25 +1,853.1%	-78.8%	$4.61M	$30.38M	N/A	40
PULM Pulmatrix	0.3868 of 5 stars	$1.29 +2.4%	N/A	-79.1%	$4.60M	$7.81M	N/A	20	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CWBR) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CohBar (CWBR) Competitors

CWBR vs. SBFM, FBLG, SNYR, PULM, and ALZN

How does CohBar compare to Sunshine Biopharma?

Summary

How does CohBar compare to FibroBiologics?

Summary

How does CohBar compare to Synergy CHC?

Summary

How does CohBar compare to Pulmatrix?

Summary

How does CohBar compare to Alzamend Neuro?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CWBR vs. The Competition

CohBar Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CohBar (CWBR) Competitors

CWBR vs. SBFM, FBLG, SNYR, PULM, and ALZN

How does CohBar compare to Sunshine Biopharma?

Do analysts recommend CWBR or SBFM?

Which has stronger valuation and earnings, CWBR or SBFM?

Does the media favor CWBR or SBFM?

Do institutionals & insiders have more ownership in CWBR or SBFM?

Is CWBR or SBFM more profitable?

Which has more risk and volatility, CWBR or SBFM?

Summary

How does CohBar compare to FibroBiologics?

Do analysts recommend CWBR or FBLG?

Which has higher valuation & earnings, CWBR or FBLG?

Does the media refer more to CWBR or FBLG?

Which has more risk & volatility, CWBR or FBLG?

Do institutionals & insiders have more ownership in CWBR or FBLG?

Is CWBR or FBLG more profitable?

Summary

How does CohBar compare to Synergy CHC?

Which has higher valuation & earnings, CWBR or SNYR?

Do institutionals & insiders have more ownership in CWBR or SNYR?

Do analysts recommend CWBR or SNYR?

Does the media refer more to CWBR or SNYR?

Is CWBR or SNYR more profitable?

Which has more risk & volatility, CWBR or SNYR?

Summary

How does CohBar compare to Pulmatrix?

Which has better earnings and valuation, PULM or CWBR?

Do institutionals and insiders have more ownership in PULM or CWBR?

Do analysts rate PULM or CWBR?

Does the media prefer PULM or CWBR?

Is PULM or CWBR more profitable?

Which has more volatility & risk, PULM or CWBR?

Summary

How does CohBar compare to Alzamend Neuro?

Which has stronger earnings & valuation, ALZN or CWBR?

Do institutionals and insiders have more ownership in ALZN or CWBR?

Does the media prefer ALZN or CWBR?

Do analysts rate ALZN or CWBR?

Which has more risk & volatility, ALZN or CWBR?

Is ALZN or CWBR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CWBR vs. The Competition

CohBar Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools